Thermo Fisher Scientific (TMO)

Thermo Fisher Scientific Inc (NYSE:TMO) is ranked as a Buy using the methodology of Louis Navellier for investing and his Portfolio Grader stock evaluator. TMO has maintained this ranking for 2 months.

Thermo Fisher Scientific Inc (NYSE:TMO) is ranked as a Buy using the system of Louis Navellier for investing and his Portfolio Grader stock evaluator. The current overall Portfolio Grader recommendation on the shares has changed twice in the past month, which represents a greater level of change than is typical.

The current recommendation of Buy for Thermo Fisher Scientific Inc (NYSE:TMO) is derived using the Portfolio Grader stock evaluator of Louis Navellier, which incorporates his investing system. The current overall Portfolio Grader recommendation on the shares has changed twice in the past month, which represents a greater level of change than is typical.

Thermo Fisher Scientific Inc (NYSE:TMO) ranks in the top 10% of its industry group, Life Sciences Tools & Services, and in the top 10% of its sector group, Health Care, with a market value of $74.7 billion. From an investment attractiveness prospective, TMO is ranked in the top half of the sector with a ranking of 311 among the 782 companies in the sector; the ranking for TMO by Portfolio Grader places it 20 among the 33 companies in this industry group, giving it a lower than average position and number 1,957 in the 5000 company Portfolio Grader company universe.

Thermo Fisher Scientific Inc (NYSE:TMO) is one of the 785 companies in the GICS Health Care sector, and a constituent of the 33 company Life Sciences Tools & Services GICS industry group within this sector. The market value of TMO is $77.7 billion which falls in the top 10% of its industry group. The ranking for TMO by Portfolio Grader places it 17 among the 33 companies in this industry group, giving it a below-average spot; in the top half of the sector with a ranking of 234 among the 785 companies in the sector, and number 1,518 in the nearly 5,000 company Portfolio Grader universe.

Portfolio Grader currently ranks Thermo Fisher Scientific Inc (NYSE:TMO) a Buy. The methodology for investing incorporated in this analytical tool developed by Louis Navellier researches and ranks nearly 5,000 stocks each week from a fundamental and quantitative perspective. TMO has recently seen its Portfolio Grader rating upgraded from a Hold to a Buy.

Portfolio Grader currently ranks Thermo Fisher Scientific Inc (NYSE:TMO) a Buy. With exclusive fundamental and quantitative metrics developed by Louis Navellier, this analytical tool evaluates nearly 5,000 stocks weekly. TMO has recently seen its Portfolio Grader rating upgraded from a Hold to a Buy.

Thermo Fisher Scientific Inc (NYSE:TMO) is one of 33 companies within the Life Sciences Tools & Services GICS industry group, which is in turn part of the 783 company GICS Health Care sector. TMO has a market value of $75.1 billion which is in the top decile in its industry group. The ranking for TMO by Portfolio Grader places it 15 among the 33 companies in this industry group, placing it in the top half; in the top half of the sector with a ranking of 204 among the 783 companies in the sector, and number 1,463 in the nearly 5,000 company Portfolio Grader universe.

The current recommendation of Buy for Thermo Fisher Scientific Inc (NYSE:TMO) is computed using the approach to investing of Louis Navellier and his Portfolio Grader stock evaluator. TMO has been upgraded from a Hold to a Buy in the last week.

The current recommendation of Buy for Thermo Fisher Scientific Inc (NYSE:TMO) is computed using the approach to investing of Louis Navellier and his Portfolio Grader stock evaluator. TMO has been upgraded from a Hold to a Buy in the last week.